Therefore, the combination of clinically in-use kinase inhibitors (e.g., against the EGFR, BRAF or MEK1/2) with NHR ligands (Table 1) is a promising avenue for dual targeting of oncogenic signaling in tumor cells and simultaneous empowerment of host immunity. The gene discussed is MAP2K1; the disease is neoplasm.